101 related articles for article (PubMed ID: 29454423)
41. Hip fracture outcomes in patients with Parkinson's disease.
Idjadi JA; Aharonoff GB; Su H; Richmond J; Egol KA; Zuckerman JD; Koval KJ
Am J Orthop (Belle Mead NJ); 2005 Jul; 34(7):341-6. PubMed ID: 16130353
[TBL] [Abstract][Full Text] [Related]
42. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Mov Disord; 2006 Jul; 21(7):924-9. PubMed ID: 16538619
[TBL] [Abstract][Full Text] [Related]
43. The prevalence and impact of self-reported hip fracture in elderly community-dwelling women: the Women's Health and Aging Study.
Hochberg MC; Williamson J; Skinner EA; Guralnik J; Kasper JD; Fried LP
Osteoporos Int; 1998; 8(4):385-9. PubMed ID: 10024910
[TBL] [Abstract][Full Text] [Related]
44. Articles retraction.
J Musculoskelet Neuronal Interact; 2018 Jun; 18(2):280. PubMed ID: 29855452
[TBL] [Abstract][Full Text] [Related]
45. Impact of Parkinson's disease on the acute care treatment and medium-term functional outcome in geriatric hip fracture patients.
Bliemel C; Oberkircher L; Eschbach DA; Lechler P; Balzer-Geldsetzer M; Ruchholtz S; Buecking B
Arch Orthop Trauma Surg; 2015 Nov; 135(11):1519-26. PubMed ID: 26253249
[TBL] [Abstract][Full Text] [Related]
46. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Sato Y; Honda Y; Iwamoto J
Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
[TBL] [Abstract][Full Text] [Related]
47. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease.
Sato Y; Iwamoto J; Honda Y
Parkinsonism Relat Disord; 2011 Jan; 17(1):22-6. PubMed ID: 21050796
[TBL] [Abstract][Full Text] [Related]
48. Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia.
Melton LJ; Leibson CL; Achenbach SJ; Bower JH; Maraganore DM; Oberg AL; Rocca WA
Mov Disord; 2006 Sep; 21(9):1361-7. PubMed ID: 16703587
[TBL] [Abstract][Full Text] [Related]
49. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study.
Hippisley-Cox J; Coupland C
BMJ; 2012 May; 344():e3427. PubMed ID: 22619194
[TBL] [Abstract][Full Text] [Related]
50. Association of seven functional polymorphisms of one-carbon metabolic pathway with total plasma homocysteine levels and susceptibility to Parkinson's disease among South Indians.
Kumudini N; Uma A; Naushad SM; Mridula R; Borgohain R; Kutala VK
Neurosci Lett; 2014 May; 568():1-5. PubMed ID: 24686188
[TBL] [Abstract][Full Text] [Related]
51. Letter to the Editor regarding "Parkinson's disease and hip fractures: Are complications and mortality rates increased?".
Gallardo-Molina N
Eur J Orthop Surg Traumatol; 2021 Jan; 31(1):199-200. PubMed ID: 32770404
[No Abstract] [Full Text] [Related]
52. [Osteoporosis often occurs in Parkinson's disease patients].
Ezzatian-Ahar S; Schwarz P; Pedersen SW
Ugeskr Laeger; 2014 Sep; 176(36):. PubMed ID: 25293858
[TBL] [Abstract][Full Text] [Related]
53. Notice of Retraction: Sato Y, et al. The Prevention of Hip Fracture With Risedronate and Ergocalciferol Plus Calcium Supplementation in Elderly Women With Alzheimer Disease: A Randomized Controlled Trial. Arch Intern Med. 2005;165(15):1737-1742.
Bauchner H; Redberg RF
JAMA Intern Med; 2016 Sep; 176(9):1256. PubMed ID: 27258431
[No Abstract] [Full Text] [Related]
54. Evaluating Outcomes for Older Patients with Parkinson's Disease or Dementia with Lewy Bodies who have been Hospitalised for Hip Fracture Surgery: Potential Impact of Drug Administration.
Enemark M; Midttun M; Winge K
Drugs Aging; 2017 May; 34(5):387-392. PubMed ID: 28349412
[TBL] [Abstract][Full Text] [Related]
55. Risk of Injurious Fall and Hip Fracture up to 26 y before the Diagnosis of Parkinson Disease: Nested Case-Control Studies in a Nationwide Cohort.
Nyström H; Nordström A; Nordström P
PLoS Med; 2016 Feb; 13(2):e1001954. PubMed ID: 26836965
[TBL] [Abstract][Full Text] [Related]
56. Plasma homocysteine level is a risk factor for osteoporotic fractures in elderly patients.
Zhu Y; Shen J; Cheng Q; Fan Y; Lin W
Clin Interv Aging; 2016; 11():1117-21. PubMed ID: 27574411
[TBL] [Abstract][Full Text] [Related]
57. Type of hip fracture in patients with Parkinson disease is associated with femoral bone mineral density.
Di Monaco M; Vallero F; Di Monaco R; Tappero R; Cavanna A
Arch Phys Med Rehabil; 2008 Dec; 89(12):2297-301. PubMed ID: 19061742
[TBL] [Abstract][Full Text] [Related]
58. Total HIP arthroplasty in patients with Parkinson's disease.
Mathew PG; Sponer P; Kucera T; Grinac M; Knízek J
Acta Medica (Hradec Kralove); 2013; 56(3):110-6. PubMed ID: 24592748
[TBL] [Abstract][Full Text] [Related]
59. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease.
Widner B; Leblhuber F; Frick B; Laich A; Artner-Dworzak E; Fuchs D
J Neural Transm (Vienna); 2002 Dec; 109(12):1445-52. PubMed ID: 12486485
[TBL] [Abstract][Full Text] [Related]
60. Homocysteine in neuropsychiatric disorders of the elderly.
Reutens S; Sachdev P
Int J Geriatr Psychiatry; 2002 Sep; 17(9):859-64. PubMed ID: 12221661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
